Doctor’s Note: May Newsletter Introduction from Dr. Eduardo Fox

Hola,

Amid blooming pollen counts and much change, I hope some effective allergy medications and the camaraderie of our colleagues provide some relief and calm in equal measure. We have important opportunities over the next month for us to support our patients and one another.

• Future of Pediatrics is only a couple of weeks away! If you haven’t yet, now is your chance to register to join us on May 29. We also have a special session for our practice administrators from 8:30 – noon.
• We play a critical role in early identification and intervention for developmental and behavioral differences. Please consider joining us for an upcoming webinar on Wednesday, June 4, a virtual Workshop for Abbreviated Autism Diagnostic Evaluations in Young Children. And, in case you missed it, use this link for a recent webinar geared toward primary care providers on Difficult Behaviors in Young Children.

I am also excited to highlight that this week we receive further affirmation of our disease prevention efforts and confirmation for the effectiveness of nirsevimab. In a systematic review and meta-analysis published in the Lancet, “nirsevimab was associated with a lower odds of RSV-related hospitalisation (odds ratio 0·17; 95% CI 0·12–0·23; I2=85·8%), a lower odds of ICU admission (0·19; 0·12–0·29; 55·6%), and a lower odds of LRTI incidence (0·25; 0·19–0·33; 35·1%) in infants aged 0–12 months.” (Sumsuzzman, Dewan Md et al. (2025). Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. The Lancet Child & Adolescent Health, Volume 0, Issue 0).

Please read in our newsletter about more resources and details regarding our network’s activities. Let us continue to lean on each other as we guide our patients through this busy season. Wishing you all a healthy and hopeful May.

Hasta luego,
Eduardo Fox, M.D.

Medical Director, PHN